Developer docs
API playgroundTry for free, no card

Search company profiles

Mongoose Bio

Full company profile

uuid0003cnd

Namestring
Mongoose Bio
Legal namestring
Mongoose Bio, Inc.
Websiteurl
mongoosebio.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Mongoose Bio, Inc. is a private clinical-stage biopharmaceutical company headquartered in Houston, Texas (2450 Holcombe Blvd., Ste. 200), spun out of MD Anderson Cancer Center in 2023 under an exclusive worldwide license to develop and commercialize TCR-T cell therapy technology developed by founder Dr. Cassian Yee over more than 20 years. The company is developing a portfolio of four epigenetically reprogrammed autologous central memory T-cell (Tcm) therapies — lead asset MGB-001 plus pipeline candidates MGB-002, MGB-003, and MGB-004 — for common and rare solid tumors including gastric/esophageal, breast, non-small cell lung, prostate, bladder, cervical, and head/neck cancers. Its technical platform has two pillars: (1) the Immunopeptidome Discovery Platform (IDP), a mass-spectrometry-based system that has generated over 2 million spectra and empirically validated 250 high-value TCR target antigens with four selected candidates covering >80% of Class I MHC (HLA); and (2) Epigenetic T Cell Reprogramming (ECMR), an IL-21 and HDACi-based protocol that drives T cells into a central memory state for in vivo persistence without high-dose lymphodepletion, enabling outpatient-compatible treatment.

The company operates a B2B enterprise model targeting academic cancer centers, hospital systems, and oncology practices that will administer the cell therapies once approved. Current revenue streams are pre-commercial: future economics will come from one-time treatment delivery in clinical settings and from potential out-licensing or co-development royalties on the MD Anderson–licensed TCR-T IP. Manufacturing for the lead program is supported by CDMO partnerships with Cellipont Bioservices (cGMP cell therapy manufacture, agreement signed October 2024) and Matica Bio (lentiviral vector production, partnership signed October 2024). The company is led by CEO Neil Warma (appointed February 2024) and founder/CSO Dr. Cassian Yee, with a small team of 1–10 employees. As of late 2024, MGB-001 is positioned to enter a Phase 1 clinical trial; no products are approved or generating commercial revenue, and the company has filed an SEC Form D indicating private capital-raising activity.

Short descriptiontext

Mongoose Bio is a clinical-stage biotech developing epigenetically reprogrammed autologous TCR-T cell therapies for solid tumors, leveraging a proprietary Immunopeptidome Discovery Platform and Epigenetic T Cell Reprogramming technology licensed exclusively from MD Anderson Cancer Center.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
TCR-T cell therapy, adoptive cell therapy, cancer immunotherapy, solid tumor treatment, epigenetic cell reprogramming
Industry3 codes
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cancer Immunotherapy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1TCR-T Cell Therapy Development and Commercialization
TypeOne Time License
Description

Development and potential commercialization of epigenetically reprogrammed autologous TCR-T cell therapies for solid tumors. The company is advancing a pipeline of four TCR-T candidates (MGB-001 through MGB-004) with lead asset MGB-001 entering Phase 1 clinical trials for multiple cancer indications. Revenue would be generated through treatment delivery in clinical settings upon regulatory approval.

mongoosebio.com
2Licensing and IP Royalties
TypeLicensing Royalties
Description

The company holds an exclusive license from MD Anderson Cancer Center to develop and commercialize TCR-T technology worldwide. As the platform is further developed, out-licensing of technology or co-development partnerships may generate revenue streams.

mongoosebio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Mongoose Bio is a clinical-stage biopharmaceutical company developing epigenetically reprogrammed autologous central memory T cell (Tcm) therapies (TCR-T) targeting highly immunogenic pan-cancer solid tumor antigens. Its pipeline includes lead asset MGB-001 and three additional candidates (MGB-002, MGB-003, MGB-004) selected through its proprietary Immunopeptidome Discovery Platform (IDP), with manufacturing enabled by Epigenetic T Cell Reprogramming (ECMR) technology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Relapse rates as high as 60% despite complete remission following CAR-T cell therapy due to lack of T cell persistence
+5 more records
Product overview1 text field

Mongoose Bio is a clinical-stage biopharmaceutical company developing a portfolio of epigenetically reprogrammed memory T cell therapies (TCR-T) for solid tumors. The company's product suite includes lead asset MGB-001 plus pipeline candidates MGB-002, MGB-003, and MGB-004, all TCR-T therapies derived from their Immunopeptidome Discovery Platform (IDP) and manufactured using their Epigenetic T Cell Reprogramming (ECMR) technology. The IDP platform enables identification of tumor-specific targets, while ECMR reprograms central memory T cells to persist long-term in vivo, addressing key limitations of conventional CAR-T and TCR-T approaches.

Product and service4 records
1MGB-001
CategoryTCR-T Cell Therapy
Description

High-affinity autologous TCR-T cell therapy targeting a cancer-testis antigen expressed in over 60% of breast cancers and approximately 45% of prostate, lung, bladder, gastric, ovarian, and head/neck cancers. Presented by HLA-A2 and A3/A11 subtypes representing >60% of global cancer patients; no off-target activity observed. Designed for solid tumor oncology use.

2MGB-002
CategoryTCR-T Cell Therapy
Description

Pre-clinical TCR-T cell therapy candidate targeting prostate, TNBC, lung, colorectal cancers and chordoma; HLA-A2/A24 restricted.

3MGB-003
CategoryTCR-T Cell Therapy
Description

Pre-clinical TCR-T cell therapy candidate targeting breast cancer; HLA-A2/A3/A11 restricted.

4MGB-004
CategoryTCR-T Cell Therapy
Description

Pre-clinical TCR-T cell therapy candidate targeting AML, bladder, breast, cervical, esophageal cancers, lymphoma, sarcoma, angiosarcoma, anaplastic thyroid cancer, and glioblastoma; HLA-A2 restricted.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-07-31
Description

Mongoose Bio was invited to join a global consortium to study the effects of microgravity on human T-cells aboard the International Space Station. The consortium, including NASA, CASIS, Axiom Space, BioServe Space Technologies, Deep Space Biology, The University of Texas, and MD Anderson, aims to uncover novel signaling pathways and identify potential immune targets. Mongoose Bio's role is to translate findings to clinical development.

Strategic tierCoreTypeTechnology or Integration
Description

Mongoose Bio was spun out of MD Anderson Cancer Center in 2023 with an exclusive worldwide license to develop and commercialize the TCR-T technology. The science and broad intellectual property were developed by Dr. Cassian Yee at MD Anderson over 20 years of research.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Adaptimmune is a clinical-stage cell therapy company developing TCR-T cell therapies for solid tumors, including MAGE-A4 and other cancer-testis antigens. It is the most direct comparable to Mongoose Bio given shared TCR-T modality, solid tumor focus, and HLA-restricted target approach.

TypeDirect peer
Description

Immatics develops TCR-T and TCR-bispecific therapies directed at tumor-specific peptides identified through its XCEPTOR and XCUBE platforms, closely mirroring Mongoose Bio's mass-spec-based immunopeptidome discovery and TCR-T pipeline. Dr. Yee has also served as a scientific advisor to Immatics.

TypeDirect peer
Description

Iovance is the leader in tumor-infiltrating lymphocyte (TIL) therapy for solid tumors, with FDA-approved lifileucel for melanoma. Mongoose Bio explicitly positions its reprogrammed TCR-T approach against TIL therapies, making Iovance the most relevant comparator for solid-tumor cell therapy adoption and pricing dynamics.

TypeDirect peer
Description

Marker Therapeutics develops multi-tumor-associated antigen (TAA)-specific T cell therapies for solid tumors and hematologic malignancies. Mongoose Bio's VP of Manufacturing previously led cell therapy manufacturing at Marker, and the companies share a TCR-based approach to broad solid tumor targeting.

TypeDirect peer
Description

Achilles Therapeutics develops personalized neoantigen-targeted T cell therapies for solid tumors using patient-specific TCR-T products. It is comparable to Mongoose Bio as a TCR-T platform for solid tumors, though Achilles focuses on patient-specific neoantigens rather than shared cancer-testis antigens.

TypeBroad incumbent
Description

Allogene is a leading allogeneic CAR-T developer with a broad pipeline across hematologic and solid tumor indications. While primarily CAR-T focused, it represents a major incumbent in cell therapy with manufacturing scale that could eventually compete in solid tumor settings where Mongoose Bio's TCR-T plays.

TypeEmerging player
Description

Cellectis is a clinical-stage gene editing company developing allogeneic CAR-T and TCR-T cell therapies. Its TALEN-based gene editing platform and TCR-T pipeline make it a relevant adjacent peer for Mongoose Bio's engineered T cell approach, though it focuses on allogeneic rather than autologous products.

TypeEmerging player
Description

Celularity develops placental-derived allogeneic cell therapies including NK and T cell candidates for oncology. It represents an emerging player in the broader cell therapy oncology space where Mongoose Bio competes for talent, capital, and clinical trial site capacity.

TypeBroad incumbent
Description

BioNTech is a large commercial-stage biopharmaceutical company with a growing cell therapy pipeline including TCR-T candidates (e.g., BNT211 for CLDN6) for solid tumors. It represents a well-capitalized broad incumbent whose progress validates the TCR-T solid tumor thesis and sets competitive benchmarks.

TypeBroad incumbent
Description

Sana Biotechnology is a clinical-stage cell therapy company developing engineered T cells and stem cell-based therapies. Its hypoimmune allogeneic platform and in vivo cell engineering programs make it a relevant broad incumbent peer in the next-generation cell therapy category where Mongoose Bio operates.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mongoose Bio

Cancer Immunotherapymongoosebio.com

Mongoose Bio is a clinical-stage biotech developing epigenetically reprogrammed autologous TCR-T cell therapies for solid tumors, leveraging a proprietary Immunopeptidome Discovery Platform and Epigenetic T Cell Reprogramming technology licensed exclusively from MD Anderson Cancer Center.

What Mongoose Bio does

Mongoose Bio, Inc. is a private clinical-stage biopharmaceutical company headquartered in Houston, Texas (2450 Holcombe Blvd., Ste. 200), spun out of MD Anderson Cancer Center in 2023 under an exclusive worldwide license to develop and commercialize TCR-T cell therapy technology developed by founder Dr. Cassian Yee over more than 20 years. The company is developing a portfolio of four epigenetically reprogrammed autologous central memory T-cell (Tcm) therapies — lead asset MGB-001 plus pipeline candidates MGB-002, MGB-003, and MGB-004 — for common and rare solid tumors including gastric/esophageal, breast, non-small cell lung, prostate, bladder, cervical, and head/neck cancers. Its technical platform has two pillars: (1) the Immunopeptidome Discovery Platform (IDP), a mass-spectrometry-based system that has generated over 2 million spectra and empirically validated 250 high-value TCR target antigens with four selected candidates covering >80% of Class I MHC (HLA); and (2) Epigenetic T Cell Reprogramming (ECMR), an IL-21 and HDACi-based protocol that drives T cells into a central memory state for in vivo persistence without high-dose lymphodepletion, enabling outpatient-compatible treatment.

The company operates a B2B enterprise model targeting academic cancer centers, hospital systems, and oncology practices that will administer the cell therapies once approved. Current revenue streams are pre-commercial: future economics will come from one-time treatment delivery in clinical settings and from potential out-licensing or co-development royalties on the MD Anderson–licensed TCR-T IP. Manufacturing for the lead program is supported by CDMO partnerships with Cellipont Bioservices (cGMP cell therapy manufacture, agreement signed October 2024) and Matica Bio (lentiviral vector production, partnership signed October 2024). The company is led by CEO Neil Warma (appointed February 2024) and founder/CSO Dr. Cassian Yee, with a small team of 1–10 employees. As of late 2024, MGB-001 is positioned to enter a Phase 1 clinical trial; no products are approved or generating commercial revenue, and the company has filed an SEC Form D indicating private capital-raising activity.

Mongoose Bio firmographics

Firmographics
Name
Mongoose Bio
Legal name
Mongoose Bio, Inc.
Website
https://mongoosebio.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
Mongoose Bio is a clinical-stage biotech developing epigenetically reprogrammed autologous TCR-T cell therapies for solid tumors, leveraging a proprietary Immunopeptidome Discovery Platform and Epigenetic T Cell Reprogramming technology licensed exclusively from MD Anderson Cancer Center.
Ownership category
akta.pro rank

Mongoose Bio industry classification

Industry
Product category
Cancer Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing

Keywords

  • TCR-T cell therapy
  • Adoptive cell therapy
  • Cancer immunotherapy
  • Solid tumor treatment
  • Epigenetic cell reprogramming

Where Mongoose Bio is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Mongoose Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. TCR-T Cell Therapy Development and Commercialization: Development and potential commercialization of epigenetically reprogrammed autologous TCR-T cell therapies for solid tumors. The company is advancing a pipeline of four TCR-T candidates (MGB-001 through MGB-004) with lead asset MGB-001 entering Phase 1 clinical trials for multiple cancer indications. Revenue would be generated through treatment delivery in clinical settings upon regulatory approval.
  2. Licensing and IP Royalties: The company holds an exclusive license from MD Anderson Cancer Center to develop and commercialize TCR-T technology worldwide. As the platform is further developed, out-licensing of technology or co-development partnerships may generate revenue streams.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Mongoose Bio product offering

Product offering

Core offering

Mongoose Bio is a clinical-stage biopharmaceutical company developing epigenetically reprogrammed autologous central memory T cell (Tcm) therapies (TCR-T) targeting highly immunogenic pan-cancer solid tumor antigens. Its pipeline includes lead asset MGB-001 and three additional candidates (MGB-002, MGB-003, MGB-004) selected through its proprietary Immunopeptidome Discovery Platform (IDP), with manufacturing enabled by Epigenetic T Cell Reprogramming (ECMR) technology.

Product overview

Mongoose Bio is a clinical-stage biopharmaceutical company developing a portfolio of epigenetically reprogrammed memory T cell therapies (TCR-T) for solid tumors. The company's product suite includes lead asset MGB-001 plus pipeline candidates MGB-002, MGB-003, and MGB-004, all TCR-T therapies derived from their Immunopeptidome Discovery Platform (IDP) and manufactured using their Epigenetic T Cell Reprogramming (ECMR) technology. The IDP platform enables identification of tumor-specific targets, while ECMR reprograms central memory T cells to persist long-term in vivo, addressing key limitations of conventional CAR-T and TCR-T approaches.

Differentiator

Problem solved

Functional benefit

Products and services

  • MGB-001 High-affinity autologous TCR-T cell therapy targeting a cancer-testis antigen expressed in over 60% of breast cancers and approximately 45% of prostate, lung, bladder, gastric, ovarian, and head/neck cancers. Presented by HLA-A2 and A3/A11 subtypes representing >60% of global cancer patients; no off-target activity observed. Designed for solid tumor oncology use.
  • MGB-002 Pre-clinical TCR-T cell therapy candidate targeting prostate, TNBC, lung, colorectal cancers and chordoma; HLA-A2/A24 restricted.
  • MGB-003 Pre-clinical TCR-T cell therapy candidate targeting breast cancer; HLA-A2/A3/A11 restricted.
  • MGB-004 Pre-clinical TCR-T cell therapy candidate targeting AML, bladder, breast, cervical, esophageal cancers, lymphoma, sarcoma, angiosarcoma, anaplastic thyroid cancer, and glioblastoma; HLA-A2 restricted.

Quantifiable outcome

  • Relapse rates as high as 60% despite complete remission following CAR-T cell therapy due to lack of T cell persistence
  • +5 more outcomes

Companies that use Mongoose Bio

Customer profile

Segments2 records

Ideal customer profiles2 records

Mongoose Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Mongoose Bio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • NASA / CASIS / ISS National LaboratoryminorStrategic or Co-development Partner · 31 July 2024Mongoose Bio was invited to join a global consortium to study the effects of microgravity on human T-cells aboard the International Space Station. The consortium, including NASA, CASIS, Axiom Space, BioServe Space Technologies, Deep Space Biology, The University of Texas, and MD Anderson, aims to uncover novel signaling pathways and identify potential immune targets. Mongoose Bio's role is to translate findings to clinical development.
  • MD Anderson Cancer CentercoreTechnology or IntegrationMongoose Bio was spun out of MD Anderson Cancer Center in 2023 with an exclusive worldwide license to develop and commercialize the TCR-T technology. The science and broad intellectual property were developed by Dr. Cassian Yee at MD Anderson over 20 years of research.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Mongoose Bio competitors and assessment

Company assessment

Direct peers

  • Adaptimmune Therapeutics: Adaptimmune is a clinical-stage cell therapy company developing TCR-T cell therapies for solid tumors, including MAGE-A4 and other cancer-testis antigens. It is the most direct comparable to Mongoose Bio given shared TCR-T modality, solid tumor focus, and HLA-restricted target approach.
  • Immatics: Immatics develops TCR-T and TCR-bispecific therapies directed at tumor-specific peptides identified through its XCEPTOR and XCUBE platforms, closely mirroring Mongoose Bio's mass-spec-based immunopeptidome discovery and TCR-T pipeline. Dr. Yee has also served as a scientific advisor to Immatics.
  • Iovance Biotherapeutics: Iovance is the leader in tumor-infiltrating lymphocyte (TIL) therapy for solid tumors, with FDA-approved lifileucel for melanoma. Mongoose Bio explicitly positions its reprogrammed TCR-T approach against TIL therapies, making Iovance the most relevant comparator for solid-tumor cell therapy adoption and pricing dynamics.
  • Marker Therapeutics: Marker Therapeutics develops multi-tumor-associated antigen (TAA)-specific T cell therapies for solid tumors and hematologic malignancies. Mongoose Bio's VP of Manufacturing previously led cell therapy manufacturing at Marker, and the companies share a TCR-based approach to broad solid tumor targeting.
  • Achilles Therapeutics: Achilles Therapeutics develops personalized neoantigen-targeted T cell therapies for solid tumors using patient-specific TCR-T products. It is comparable to Mongoose Bio as a TCR-T platform for solid tumors, though Achilles focuses on patient-specific neoantigens rather than shared cancer-testis antigens.

Broad incumbents

  • Allogene Therapeutics: Allogene is a leading allogeneic CAR-T developer with a broad pipeline across hematologic and solid tumor indications. While primarily CAR-T focused, it represents a major incumbent in cell therapy with manufacturing scale that could eventually compete in solid tumor settings where Mongoose Bio's TCR-T plays.
  • BioNTech: BioNTech is a large commercial-stage biopharmaceutical company with a growing cell therapy pipeline including TCR-T candidates (e.g., BNT211 for CLDN6) for solid tumors. It represents a well-capitalized broad incumbent whose progress validates the TCR-T solid tumor thesis and sets competitive benchmarks.
  • Sana Biotechnology: Sana Biotechnology is a clinical-stage cell therapy company developing engineered T cells and stem cell-based therapies. Its hypoimmune allogeneic platform and in vivo cell engineering programs make it a relevant broad incumbent peer in the next-generation cell therapy category where Mongoose Bio operates.

Emerging players

  • Cellectis: Cellectis is a clinical-stage gene editing company developing allogeneic CAR-T and TCR-T cell therapies. Its TALEN-based gene editing platform and TCR-T pipeline make it a relevant adjacent peer for Mongoose Bio's engineered T cell approach, though it focuses on allogeneic rather than autologous products.
  • Celularity: Celularity develops placental-derived allogeneic cell therapies including NK and T cell candidates for oncology. It represents an emerging player in the broader cell therapy oncology space where Mongoose Bio competes for talent, capital, and clinical trial site capacity.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Mongoose Bio social profiles

Digital presence

Mongoose Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mongoose Bio leadership team

Management profile

Number of profiles

Profiles5 records

Mongoose Bio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mongoose Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mongoose Bio

What does Mongoose Bio do?

Mongoose Bio is a clinical-stage biopharmaceutical company developing epigenetically reprogrammed autologous central memory T cell (Tcm) therapies (TCR-T) targeting highly immunogenic pan-cancer solid tumor antigens. Its pipeline includes lead asset MGB-001 and three additional candidates (MGB-002, MGB-003, MGB-004) selected through its proprietary Immunopeptidome Discovery Platform (IDP), with manufacturing enabled by Epigenetic T Cell Reprogramming (ECMR) technology.

Is Mongoose Bio a public or private company?

Mongoose Bio is a private company. It is classified as unknown and is currently operating.

When was Mongoose Bio founded?

Mongoose Bio was founded in 2023. It employs 1 to 10 people.

Where is Mongoose Bio based?

Mongoose Bio is headquartered in Houston, United States, in the North America region.

How does Mongoose Bio make money?

Two revenue lines are on record. TCR-T Cell Therapy Development and Commercialization is the primary driver. The others are licensing and IP Royalties.

Who are Mongoose Bio's main competitors?

Direct peers on record are Adaptimmune Therapeutics, Immatics, Iovance Biotherapeutics, Marker Therapeutics and Achilles Therapeutics. Broad incumbents are Allogene Therapeutics, BioNTech and Sana Biotechnology. Emerging players are Cellectis and Celularity.

Does Mongoose Bio have an API?

No public API is recorded for Mongoose Bio.

What industry is Mongoose Bio in?

Mongoose Bio's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAGANAB, Proteomics & Mass Spectrometry Services. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals